Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors  by Hirashiki, Akihiro et al.
Gene Polymorphisms and CAD
Association of Gene Polymorphisms With
Coronary Artery Disease in Low- or High-Risk
Subjects Defined by Conventional Risk Factors
Akihiro Hirashiki, MD,* Yoshiji Yamada, MD, PHD,† Yosuke Murase, MD,* Yoriyasu Suzuki, MD,*
Hiroki Kataoka, MD,* Yasutsugu Morimoto, MD,* Toru Tajika, MD,* Toyoaki Murohara, MD, PHD,‡
Mitsuhiro Yokota, MD, PHD, FACC§
Okazaki, Kakamigahara, and Nagoya, Japan
OBJECTIVES The aim of the study was to identify genes that confer susceptibility to coronary artery disease
(CAD) in low- or high-risk men or women separately and thereby to assess the genetic risk
of CAD in such individuals.
BACKGROUND The prevention of CAD would be facilitated by the identification of genes that confer
susceptibility to this condition independently in low- or high-risk individuals, as defined by
conventional risk factors.
METHODS The study population comprised 1,661 unrelated Japanese individuals, including 1,011
patients with CAD and 650 control subjects. Among all study subjects, 601 individuals
(high-risk subjects) had hypertension, diabetes mellitus, and hypercholesterolemia, and 1,060
individuals (low-risk subjects) had none of these risk factors for CAD. The genotypes for 37
polymorphisms of 31 candidate genes were determined by a fluorescence- or colorimetry-
based allele-specific DNA primer-probe assay system.
RESULTS Multivariate logistic regression analysis, with adjustment for age, body mass index, and the
prevalence of smoking and hyperuricemia, revealed that the219G3T polymorphism of the
apolipoprotein E gene in low-risk men, the 1171/5A36A polymorphism of the
stromelysin-1 gene in low-risk women, the 1019C3T polymorphism of the connexin 37
gene in high-risk men, and the 3932T3C polymorphism of the apolipoprotein E gene in
high-risk women were significantly associated with CAD. A stepwise forward selection
procedure revealed that the effects of these polymorphisms on CAD were statistically
independent of age or conventional risk factors.
CONCLUSIONS Genotyping of these polymorphisms may prove informative for assessment of the genetic risk
of CAD in low- or high-risk men or women. (J Am Coll Cardiol 2003;42:1429–37)
© 2003 by the American College of Cardiology Foundation
Coronary artery disease (CAD) is a multifactorial disorder
that is thought to result from an interaction between genetic
background and environmental factors such as diet, smok-
ing, and physical activity. It is usually associated with
conventional risk factors, including hypertension, diabetes
mellitus, and hypercholesterolemia (1). However, in some
individuals, CAD is not associated with such risk factors,
suggesting that other genetic factors contribute to a predis-
position to coronary atherosclerosis and its thrombotic
complications (2). In general, individuals with hypertension,
diabetes mellitus, and hypercholesterolemia and those with
none of these factors are considered at high and low risk,
respectively, for development of CAD. It is thus important
to identify genes that confer susceptibility to CAD in these
high- and low-risk individuals independently.
Genetic epidemiologic studies have suggested that
certain genetic variants, including polymorphisms in the
genes encoding platelet glycoprotein IIIa (3), methylene-
tetrahydrofolate reductase (4), and plasminogen-activator
inhibitor-1 (5), are associated with an increased prevalence
of CAD in high- or low-risk subjects. However, the genes
that contribute to genetic susceptibility to CAD in individ-
uals with three major conventional risk factors—
hypertension, diabetes mellitus, and hypercholesterol-
emia—or in those with none of these factors remain to be
identified. In addition, because of ethnic divergence of gene
polymorphisms, it is important to examine polymorphisms
related to CAD in low- or high-risk individuals of each
ethnic group.
In a previous association study of 112 polymorphisms in
71 genes of 445 individuals with myocardial infarction (MI)
and 464 control subjects, we identified 19 and 18 polymor-
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phisms that are possibly related to MI in Japanese men and
women, respectively (6). We have performed an association
study for 37 polymorphisms of 31 candidate genes (includ-
ing the polymorphisms previously related to MI) and CAD
in the absence or presence of hypertension, diabetes melli-
tus, and hypercholesterolemia. Our aim was to identify
genes that confer susceptibility to CAD in low- or high-risk
men or women independently and thereby to assess the
genetic risk of CAD in such individuals separately.
METHODS
Study population. The study population comprised 1,661
unrelated Japanese individuals (1,060 men and 601 women)
who either visited outpatient clinics of or were admitted to
one of the participating hospitals (Appendix) between July
1994 and December 2001, either because they were expe-
riencing various symptoms or for a medical checkup and
who were found to have either hypertension (systolic blood
pressure [BP] 140 mm Hg or diastolic BP 90 mm Hg,
or both), diabetes mellitus (fasting blood glucose 6.93
mmol/l or glycosylated hemoglobin [HbA1c] 6.5%, or
both), and hypercholesterolemia (serum total cholesterol
5.72 mmol/l) or none of these major risk factors for CAD.
A total of 1,011 subjects (696 men and 315 women) had
CAD; all of these individuals underwent coronary angiog-
raphy and left ventriculography. The diagnosis of CAD was
defined as 50% stenosis in any major coronary artery, as
revealed by coronary angiography. Among the 1,011 CAD
subjects, 744 (535 men and 209 women) had MI. The 650
control subjects (364 men and 286 women) exhibited
normal electrocardiograms at rest and no signs of myocar-
dial ischemia during exercise stress testing; these examina-
tions were performed in control subjects as part of a medical
checkup in the absence of cardiovascular symptoms. Among
all 1,661 study subjects, the 601 individuals (364 men and
237 women) with hypertension, diabetes mellitus, and
hypercholesterolemia were classified as high risk, and the
1,060 individuals (696 men and 364 women) with none of
these conditions were classified as low risk. Individuals with
valvular heart disease, congenital malformations of the heart
or vessels, or metabolic or endocrinologic diseases, as well as
those taking drugs that cause secondary hypertension, dia-
betes mellitus, or hypercholesterolemia, were excluded from
the study. The study protocol was approved by the Com-
mittees on the Ethics of Human Research of Nagoya
University Graduate School of Medicine, Gifu Interna-
tional Institute of Biotechnology, Okazaki City Hospital,
Kosei Hospital, and Nagoya Daini Red Cross Hospital, and
written, informed consent was obtained from each
participant.
Selection of candidate gene polymorphisms for CAD.
We previously performed a screening association study with
112 polymorphisms of 71 genes in 451 men (219 patients
with MI and 232 controls) and 458 women (226 patients
with MI and 232 controls) (6). From this screening study,
we identified 19 and 18 polymorphisms possibly related to
MI (p  0.1) in men and women, respectively (four
polymorphisms were related to MI in both men and
women). In addition to these 33 polymorphisms of 27
genes, for the present study we selected four polymorphisms
of four genes (angiotensin I-converting enzyme, angiotensin
II receptor type 1, glycoprotein IIIa, and methylenetetrahy-
drofolate reductase genes) that have been associated with
cardiovascular disease. Most of the 37 polymorphisms of
these 31 genes are located in the promoter region, exons, or
splice donor or acceptor sites in introns and might be
expected to affect the function of the encoded protein or its
expression (Table 1). We therefore examined the possible
association of these 37 polymorphisms with CAD.
Genotyping of polymorphisms. Venous blood (7 ml) was
collected from each subject into tubes containing 50 mmol/l
EDTA (disodium salt), and genomic DNA was isolated
with a kit (Qiagen, Chatsworth, California). The genotypes
of polymorphisms were determined by a fluorescence- or
colorimetry-based allele-specific DNA primer-probe assay
system, as previously described (6) (Table 2).
Statistical analysis. Quantitative clinical data were com-
pared between patients with CAD and control subjects by
the unpaired Student t test. Qualitative data were compared
by the chi-square test. Allele frequencies were estimated by
the gene counting method, and the chi-square test was used
to identify significant departures from the Hardy-Weinberg
equilibrium. We performed multivariate logistic regression
analysis to adjust risk factors, with CAD as a dependent
variable and age, gender, body mass index (BMI), smoking
status (0  nonsmoker; 1  smoker), hyperuricemia (0 
no history; 1  positive history), and the genotype of each
polymorphism as independent variables. Each genotype was
assessed according to dominant, recessive, and additive
genetic models, and the p value, odds ratio, and 95%
confidence interval were calculated (JMP version 5; SAS
Institute, Cary, North Carolina). We also performed a
stepwise forward selection procedure to examine the effects
of genotypes as well as other characteristics on CAD. Unless
indicated otherwise, a p value 0.05 was considered statis-
tically significant.
RESULTS
We first examined the relation of 37 gene polymorphisms to
CAD in the total study population of 1,661 subjects, whose
characteristics are shown in Table 3. Age and the percentage
Abbreviations and Acronyms
BMI  body mass index
BP  blood pressure
CAD  coronary artery disease
HbA1c  glycosylated hemoglobin
LDL  low-density lipoprotein
MI  myocardial infarction
SNP  single nucleotide polymorphism
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Table 1. Gene Polymorphisms Examined for Association With Coronary Artery Disease
Gene Symbol Polymorphism Function of Protein
Angiotensin I-converting enzyme ACE Insertion/deletion in intron 16 Conversion of angiotensin I to angiotensin II
Angiotensin II receptor type 1 AGTR1 535C3T Type 1 cell surface receptor for angiotensin II
Angiotensinogen AGT 6G3A Precursor of angiotensin I
Apolipoprotein C-III APOC3 482C3T Major component of triglyceride-rich lipoprotein and HDL
Apolipoprotein C-III APOC3 1100C3T
Apolipoprotein E APOE 219G3T Component of chylomicrons and very-low-density
lipoprotein remnants and ligand for the LDL receptor
and LDL receptor-like protein
Apolipoprotein E APOE 3932T3C (Cys112Arg)
Apolipoprotein E APOE 4070C3T (Arg158Cys)
ATP-binding cassette transporter-1 TAP1 1051G3A (Arg219Lys) Cholesterol efflux pump in cellular lipid removal pathway
CD14 CD14 260C3T Myeloid cell surface receptor for lipopolysaccharide
CC chemokine receptor-2 CCR2 190G3A (Val64Ile) Receptor for monocyte chemoattractant protein-1
Connexin-37 GJA4 1019C3T (Pro319Ser) Gap junction component in endothelium and other tissues
Endothelial nitric oxide synthase NOS3 786T3C Production of nitric oxide from L-arginine
Endothelin-1 EDN1 5665G3T (Lys198Asn) Vasoconstrictor produced by vascular endothelial cells
E-selectin SELE 561A3C (Ser128Arg) Adhesion of leukocytes to vascular endothelial cells
Fatty acid-binding protein-2 FABP2 2445G3A (Ala54Thr) Uptake, metabolism, and transport of long-chain fatty acids
G protein 3 subunit GNB3 825C3T (splice variant) Signal transduction by pertussis toxin–sensitive G proteins
Glycoprotein IIIa ITGB3 1565T3C (Leu33Pro) Platelet receptor for fibrinogen and von Willebrand factor
Glycoprotein Ia ITGA2 1648A3G (Lys505Glu) Collagen receptor on platelets and other cell types
Glycoprotein Ib-alpha GPIBB 1018C3T (Thr145Met) Platelet surface receptor for von Willebrand factor
Insulin receptor substrate-1 IRS1 3494G3A (Gly972Arg) Substrate of insulin receptor tyrosine kinase
Interleukin-6 IL6 634C3G Promotion and regulation of acute inflammatory response
Interleukin-10 IL10 819T3C Anti-inflammatory cytokine that inhibits cytotoxic activity
of and cytokine synthesis by macrophages
Interleukin-10 IL10 592A3C
5,10-methylenetetrahydrofolate reductase MTHFR 677C3T (Ala222Val) Catalysis of the methylation of homocysteine
NADH/NADPH oxidase p22 phox p22-PHOX 242C3T (His72Tyr) Production of superoxide in vascular cells
Paraoxonase-1 PON1 584G3A (Gln192Arg) Confers antioxidant properties on HDL
Plasminogen activator inhibitor-1 PAI1 668/4G35G Inhibition of the conversion of plasminogen to plasmin
Platelet-activating factor acetylhydrolase PLA2G7 994G3T (Val279Phe) Hydrolysis of platelet-activating factor and related lipids
Stromelysin-1 MMP3 1171/5A36A Matrix metalloproteinase with a broad substrate specificity
Thrombomodulin THBD 2136C3T (Ala455Val) Vascular endothelial cell surface receptor for thrombin
Thrombopoietin THPO 5713A3G Stimulation of platelet production from megakaryocytes
Thrombospondin-4 THBS4 1186G3C (Ala387Pro) Cell adhesion, angiogenesis, and ligand for CD36
Transforming growth factor-beta1 TGFB1 869T3C (Leu10Pro) Regulates cell proliferation, differentiation, and function
Tumor necrosis factor-alpha TNFA 863C3A Pro-inflammatory cytokine with effects on lipid metabolism,
blood coagulation, insulin resistance, and vascular
endothelial function
Tumor necrosis factor-alpha TNFA 850C3T
Tumor necrosis factor-alpha TNFA 238G3A
ATP  adenosine triphosphate; HDL and LDL  high- and low-density lipoprotein, respectively. 1431
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Table 2. Primers, Probes, and Other Conditions for Genotyping
Gene SNP Labels Primers (533) Cycles Probes (533) Formamide
Apolipoprotein C-III 482C3T CGGAGCCACTGATGCXCG AGCCACTGATGCXCGGTCT
CGGAGCCACTGATGCXTG 35 AGCCACTGATGCXTGGTCT 30%
Biotin TGTTTGGAGTAAAGGCACAGAA
Apolipoprotein E 219G3T FITC GAATGGAGGAGGGTGTCTXGA
TxR AGAATGGAGGAGGGTGTCTXTA 35
Biotin CCAGGAAGGGAGGACACCTC
Apolipoprotein E 3932T3C FITC GGACATGGAGGACGTXCG
TxR CGGACATGGAGGACGTXTG 40
Biotin CGCGGTACTGCACCAGGC
CC chemokine receptor 2 190G3A FITC GCAGTTTATTAAGATGAGGXCG
TxR TTGCAGTTTATTAAGATGAGGXTG 40
Biotin GGTGCTCCCTGTCATAAATTTGA
Connexin 37 1019C3T TxR CTCAGAATGGCCAAAAXCC
FITC CCTCAGAATGGCCAAAAXTC 35
Biotin GCAGAGCTGCTGGGACGA
Endothelial nitric oxide synthase 786T3C TxR ATCAAGCTCTTCCCTGGXCG
FITC ATCAAGCTCTTCCCTGGXTG 35
Biotin TCAGCAGAGAGACTAGGGCTGA
E-selectin 561A3C ACATTCACCGTGGCCAXTG CACCGTGGCCAXTGCAGGAT
CATTCACCGTGGCCAXGG 35 CACCGTGGCCAXGGCAGGAT 45%
Biotin AGCTGCCTGTACCAATACATCC
Fatty acid-binding protein 2 2445G3A TCACAGTCAAAGAATCAAGXGC GAATCAAGXGCTTTTCGAAACATT
ATTCACAGTCAAAGAATCAAGXAC 40 GAATCAAGXACTTTTCGAAACATT 37.5%
Biotin CAAAAACAACTTCAATGTTTCGA
Glycoprotein Ib 1018C3T FITC CCCAGGGCTCCTGXCG
TxR CCCCAGGGCTCCTGXTG 40
Biotin TGAGCTTCTCCAGCTTGGGTG
Insulin receptor substrate-1 3494G3A GGGCCCTGCACCTCCXGG CACCTCCXGGGGCTGCTAG
GGGCCCTGCACCTCCXAG 40 CACCTCCXAGGGCTGCTAG 35%
Biotin GGGTAGGCCTGCAAATGCTA
Interleukin-10 819T3C TACCCTTGTACAGGTGATGTAXTA GTACAGGTGATGTAXTATCTCTGTG
TACCCTTGTACAGGTGATGTAXCA 35 GTACAGGTGATGTAXCATCTCTGTG 40%
Biotin ATAGTGAGCAAACTGAGGCACA
Interleukin-10 592A3C FITC CAGAGACTGGCTTCCTACAXGA
TxR CCAGAGACTGGCTTCCTACAXTA 35
Biotin GCCTGGAACACATCCTGTGA
NADH/NADPH oxidase p22 phox 242C3T FITC ACCACGGCGGTCATGXGC
TxR ACCACGGCGGTCATGXAC 40
Biotin GCAGCAAAGGAGTCCCGAGT
Platelet-activating factor acetylhydrolase 994G3T FITC TTCTTTTGGTGGAGCAACXGT
TxR ATTCTTTTGGTGGAGCAACXTT 40
Biotin TCTTACCTGAATCTCTGATCTTCA
Stromelysin-1 1171/5A36A FITC TTTGATGGGGGGAAAAXAC
TxR TTGATGGGGGGAAAAXCC 40
Biotin CCTCATATCAATGTGGCCAA
Thrombomodulin 2136C3T FITC CCCGACTCGGCCCTTXCC
TxR CCCGACTCGGCCCTTXTC 40
Biotin GTCACAGTCGGTGCCAATGT
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of men were greater among subjects with CAD than among
controls. Multivariate logistic regression analysis with ad-
justment for age, gender, BMI, and the prevalence of
smoking and hyperuricemia revealed that 10 single nucleo-
tide polymorphisms (SNPs) were related to CAD in the
total study population on the basis of a p value 0.05 in a
dominant, recessive, or additive genetic model (Table 4).
We next divided the study population into men and
women as well as low- and high-risk individuals. The
characteristics of the 1,060 male subjects are shown in Table
5. For low-risk men, age was higher and the prevalence of
smoking was lower in subjects with CAD than in controls.
For high-risk men, age and the prevalence of hyperuricemia
were higher in subjects with CAD than in controls. There
were no differences in systolic or diastolic BP, fasting blood
glucose, HbA1c in blood, or the serum concentration of total
cholesterol between CAD patients and controls for either
low- or high-risk men. The characteristics of the 601 female
subjects are shown in Table 6. For low-risk women, age and
BMI were higher and the prevalence of hyperuricemia was
lower in subjects with CAD than in controls. For high-risk
women, the prevalence of hyperuricemia was higher in
subjects with CAD than in controls. There were no differ-
ences in systolic or diastolic BP, fasting blood glucose,
HbA1c in blood, or the serum concentration of total
cholesterol between CAD patients and controls for either
low- or high-risk women.
Multivariate logistic regression analysis with adjustment
for age, BMI, and the prevalence of smoking and hyperuri-
cemia revealed that three and eight SNPs were related to
CAD in low- and high-risk men, respectively (Table 7), and
that four and three SNPs were related to CAD in low- and
high-risk women, respectively (Table 8), on the basis of a p
value 0.05 in a dominant, recessive, or additive genetic
model. However, because of the multiple comparisons of
genotypes, we considered a p value 0.005 to be significant
for such associations. On the basis of this criterion, the
219G3T SNP of the apolipoprotein E gene (APOE) was
significantly associated with CAD in low-risk men, and the
1019C3T SNP of the connexin 37 gene (GJA4) was
associated with CAD in high-risk men (Table 7). Also, the
1171/5A36A SNP of the stromelysin-1 gene (MMP3)
was significantly associated with CAD in low-risk women,
and the 3932T3C SNP of APOE was associated with
CAD in high-risk women (Table 8). Each SNP signifi-
cantly associated with CAD in each subgroup was not
related to CAD in the other subgroups. The 219G3T
SNP of APOE in low-risk men (p  0.0035; 370 subjects
with MI) and the 1019C3T SNP of GJA4 in high-risk
men (p  0.0243; 165 subjects with MI) were also associ-
ated with MI, but the p values for this association were
larger than those for CAD. The 1171/5A36A SNP of
MMP3 in low-risk women (128 subjects with MI) and the
3932T3C SNP of APOE in high-risk women (81 subjects
with MI) were not associated with MI.
Finally, we performed a stepwise forward selection pro-
cedure to examine the effects of genotypes for APOE
(219G3T and 3932T3C), GJA4, and MMP3, as well as
other CAD characteristics (Table 9). Age, APOE
(219G3T) genotype, and smoking, in descending order
of statistical significance, affected the prevalence of CAD in
low-risk men, and the GJA4 genotype, age, and hyperuri-
cemia influenced the prevalence of CAD in high-risk men.
Age, the MMP3 genotype, and hyperuricemia, in descend-
ing order of statistical significance, affected the prevalence of
CAD in low-risk women, whereas the APOE (3932T3C)
Table 4. Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in the Total
Study Population
Gene Polymorphism
Dominant Recessive Additive
p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI)
MMP3 1171/5A36A 0.0352 3.0 (1.0–7.1) 0.2410 0.0221 3.3 (1.1–7.8)
GJA4 1019C3T (Pro319Ser) 0.0241 1.3 (1.1–1.6) 0.0417 1.8 (1.0–3.2) 0.0332 1.9 (1.1–3.4)
APOE 3932T3C (Cys112Arg) 0.0352 2.0 (1.0–3.5) 0.5487 0.0434 2.2 (1.1–3.7)
FABP2 2445G3A (Ala54Thr) 0.6459 0.0362 2.1 (1.2–3.7) 0.0371 2.0 (1.1–3.7)
p22-PHOX 242C3T (His72Tyr) 0.0455 0.6 (0.5–0.9) 0.4549 0.0363 0.6 (0.4–0.8)
SELE 561A3C (Ser128Arg) 0.0564 0.8485 0.0364 0.3 (0.2–0.8)
IRS1 3494G3A (Gly972Arg) 0.0434 1.8 (1.1–3.0) 0.7058 0.0371 2.0 (1.2–3.3)
APOE 219G3T 0.5971 0.0401 1.5 (1.1–2.0) 0.2139
APOC3 482C3T 0.9782 0.0431 1.3 (1.0–1.7) 0.1350
NOS3 786T3C 0.0515 0.9576 0.0484 1.5 (1.0–2.2)
The lowest p value among dominant, recessive, and additive models for each polymorphism is shown in boldface.
CI  confidence interval; OR  odds ratio.
Table 3. Characteristics of All Study Subjects
Characteristic
Controls
(n  650)
Subjects With CAD
(n  1,011)
Age (yrs) 55.9  11.5 62.8  9.8*
Men/women (%) 56.0/44.0 68.8/31.2*
Body mass index (kg/m2) 23.2  3.0 23.4  3.0
Smoking (%) 40.2 40.9
Hypertension (%) 34.2 37.5
Diabetes mellitus (%) 34.2 37.5
Hypercholesterolemia (%) 34.2 37.5
Hyperuricemia (%) 8.6 11.6
*p  0.0001 versus corresponding controls. Data for age and body mass index are
presented as the mean value  SD.
CAD  coronary artery disease.
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genotype and age influenced the prevalence of CAD in
high-risk women.
DISCUSSION
Coronary atherosclerosis results from excessive inflamma-
tory and fibroproliferative responses to various forms of
insult to the endothelium and smooth muscle of the artery
wall, with the participation of large numbers of growth
factors, cytokines, and vasoregulatory molecules (7). The
genes shown to be significantly associated with CAD in the
present study play important roles in lipid metabolism
(APOE), gap-junctional communication between vascular
endothelial cells (GJA4), and vascular matrix metabolism
(MMP3).
Given that interactions between genetic and environmen-
tal factors may be important in the etiology of CAD, we
examined the effects of genotypes, as well as age, BMI, and
the prevalence of smoking and hyperuricemia, on the
prevalence of CAD in low- or high-risk men or women. An
examination of possible interactions among gene polymor-
phisms was not a purpose of the present study. A stepwise
forward selection procedure revealed that genotypes for
APOE (219G3T or 3932T3C), GJA4, or MMP3
significantly influenced the prevalence of CAD in low- or
high-risk men or women, and that the effects of these
genetic factors were statistically independent of age, smok-
ing, or hyperuricemia, as well as hypertension, diabetes
mellitus, and hypercholesterolemia. Our present results
indicate that smoking is an important environmental factor
for CAD in low-risk men, consistent with the notion that
the cessation of smoking is important in the prevention of
CAD in these individuals.
Among the total of four SNPs of three genes significantly
associated with CAD in the present study, 219G3T of
APOE was associated with CAD in low-risk men, and
1171/5A36A of MMP3 was associated with CAD in
low-risk women. Apolipoprotein E is a structural compo-
nent of both chylomicrons and very-low-density lipoprotein
remnants, and it is responsible for the binding and uptake of
these particles by the low-density lipoprotein (LDL) recep-
tor and LDL receptor-like protein (8,9). The 219G3T
SNP of APOE was previously associated with MI for men in
France and Northern Ireland, with the T allele representing
a risk factor for MI (10). Consistent with its location in the
promoter region of APOE, the219G3T SNP was shown
to be associated with the plasma concentration of apoli-
poprotein E, with the T allele conferring a reduced apoli-
poprotein E concentration (10). The deleterious influence
of the T allele on MI therefore cannot be explained by its
effect on the circulating level of apolipoprotein E. We have
Table 5. Characteristics of the 1,060 Male Study Subjects With a Low- or High-Risk of Coronary Artery Disease
Characteristic
Low-Risk Men (n  696) High-Risk Men (n  364)
Controls
(n  248)
Subjects With CAD
(n  448)
Controls
(n  116)
Subjects With CAD
(n  248)
Age (yrs) 52.6  10.9 61.8  9.7* 57.4  9.6 60.7  8.8†
Body mass index (kg/m2) 23.1  2.7 22.9  2.7 24.6  2.8 24.5  2.7
Smoking (%) 62.1 46.0* 65.5 66.1
Hyperuricemia (%) 9.3 8.0 12.1 21.8‡
Systolic blood pressure (mm Hg) 118.8  10.3 120.4  11.1 159.0  22.1 158.5  19.2
Diastolic blood pressure (mm Hg) 71.4  8.9 70.7  8.6 95.2  14.6 94.6  14.1
Fasting blood glucose (mmol/l) 5.45  0.59 5.41  0.65 9.19  2.45 9.30  2.68
Glycosylated hemoglobin (%) 4.9  0.2 5.2  0.4 7.5  1.2 7.8  1.6
Serum total cholesterol (mmol/l) 4.70  0.57 4.66  0.61 6.40  0.60 6.36  0.63
*p  0.0001, †p  0.005, and ‡p  0.05 versus corresponding controls. Data for age and body mass index are presented as the mean value  SD.
CAD  coronary artery disease.
Table 6. Characteristics of the 601 Female Study Subjects With a Low- or High-Risk for Coronary Artery Disease
Characteristic
Low-Risk Women (n  364) High-Risk Women (n  237)
Controls
(n  180)
Subjects With CAD
(n  184)
Controls
(n  106)
Subjects With CAD
(n  131)
Age (yrs) 55.2  12.4 66.4  11.1* 63.4  9.6 65.5  8.4
Body mass index (kg/m2) 21.7  2.7 22.3  2.9† 24.6  3.2 24.6  3.7
Smoking (%) 10.6 13.0 11.3 15.3
Hyperuricemia (%) 5.0 1.1† 9.4 19.1†
Systolic blood pressure (mm Hg) 119.6  13.4 120.1  10.7 169.5  23.1 170.6  23.4
Diastolic blood pressure (mm Hg) 69.6  9.3 70.0  10.3 96.1  15.5 95.1  16.2
Fasting blood glucose (mmol/l) 5.24  0.57 5.33  0.68 9.41  2.69 9.32  2.53
Glycosylated hemoglobin (%) 5.1  0.5 5.2  0.4 7.8  1.2 7.6  1.4
Serum total cholesterol (mmol/l) 4.76  0.64 4.77  0.68 6.44  0.69 6.41  0.59
*p  0.0001 and †p  0.05 versus corresponding controls. Data for age and body mass index are presented as the mean value  SD.
CAD  coronary artery disease.
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shown that the T allele of this SNP is a risk factor for CAD
in low-risk men, consistent with the previous observation
for MI (10).
Stromelysin-1 is a member of the matrix metalloprotein-
ase family, with a broad substrate specificity (11). Thus, it
catalyzes the degradation of many of the constituents of the
extracellular matrix found in atherosclerotic plaques (11).
The 1171/5A36A SNP of MMP3 has been associated
with promoter activity, with the 6A allele showing reduced
gene transcription (12). The 6A allele of the 1171/
5A36A SNP was also previously associated with an in-
creased rate of progression of coronary atherosclerosis in a
male population in England (13). Moreover, the 6A/6A
genotype was associated with an increased intima-media
thickness of the carotid artery both in Finnish men (14) and
men and women in New York (15). Consistent with these
previous observations (13–15), we have now shown that the
6A allele is a risk factor for CAD in low-risk women.
The 1019C3T SNP of GJA4 was significantly associ-
ated with CAD in high-risk men, whereas the 3932T3C
SNP of APOE was associated with CAD in high-risk
women. Connexin 37 is a gap junction protein in the arterial
endothelium, including that of human coronary arteries,
and contributes to the growth and regeneration after injury
of endothelial cells (16,17). It forms functional intercellular
channels with a voltage dependence and unitary conduc-
tance properties that are distinct from those of other
channels (18). The carboxyl terminal domain of this protein
also plays a role in pH regulation (19). The 1019C3T
(Pro319Ser) SNP of GJA4 was previously associated with
carotid intimal thickening in Swedish men, with the C allele
being overrepresented in individuals with atherosclerotic
plaques (20). The C allele of this SNP was also associated
with CAD in a Taiwanese population (21). However, the
population sizes of both of these previous studies were
small. In contrast to their findings, we have shown that the
T allele of this polymorphism is a risk factor for CAD in
high-risk men, with an odds ratio of 7.5, the highest such
value obtained in the present study. The functional impact
of the 1019C3T SNP of GJA4 has not been determined.
In humans, three alleles (2, 3, 4) of APOE have been
described. The C allele of the 3932T3C (Cys112Arg)
SNP of APOE, which is located in the LDL receptor-
binding domain of the encoded protein (8), is a major
determinant of the 4 allele, which is associated with a
reduced binding of triglyceride-rich lipoproteins to the
Table 7. Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in Low- or High-
Risk Men
Gene Polymorphism
Dominant Recessive Additive
p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI)
Low-risk men
APOE 219G3T 0.2336 0.0002 2.0 (1.4–2.8) 0.0336 2.0 (1.0–3.7)
CCR2 190G3A (Val64Ile) 0.0809 0.0080 2.8 (1.4–6.3) 0.0051 3.0 (1.4–6.9)
IL10 819T3C 0.8048 0.0309 0.5 (0.3–0.9) 0.0547
High-risk men
GJA4 1019C3T (Pro319Ser) 0.1475 0.0017 7.3 (2.3–28.2) 0.0015 7.5 (2.3–29.4)
IL10 592A3C 0.0517 0.0169 2.7 (1.3–6.7) 0.0098 3.1 (1.4–7.6)
IL10 819T3C 0.0688 0.0155 2.8 (1.3–6.9) 0.0102 3.1 (1.4–7.8)
CCR2 190G3A (Val64Ile) 0.2051 0.0139 2.5 (1.2–5.3) 0.0129 2.6 (1.2–5.7)
p22-PHOX 242C3T (His72Tyr) 0.0143 0.5 (0.3–0.9) 0.8458 0.0130 0.5 (0.3–0.9)
PLA2G7 994G3T (Val279Phe) 0.0143 2.0 (1.2–3.5) 0.7889 0.0466 1.8 (1.0–3.2)
THMD 2136C3T (Ala455Val) 0.3491 0.0336 0.4 (0.2–0.9) 0.0330 0.4 (0.2–0.9)
NOS3 786T3C 0.0369 1.9 (1.1–3.7) 0.8611 0.0497 1.9 (1.0–3.8)
The lowest p value among dominant, recessive, and additive models for each polymorphism is shown in boldface.
CI  confidence interval; OR  odds ratio.
Table 8. Multivariate Logistic Regression Analysis of Polymorphisms Associated With Coronary Artery Disease in Low- or High-
Risk Women
Gene Polymorphism
Dominant Recessive Additive
p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI)
Low-risk women
MMP3 1171/5A36A 0.0034 2.9 (1.4–6.0) 0.1069 0.0049 2.9 (1.4–6.0)
GP1BB 1018C3T (Thr145Met) 0.0123 0.4 (0.2–0.8) 0.5273 0.0154 0.4 (0.2–0.8)
IRS1 3494G3A (Gly972Arg) 0.0132 4.4 (1.4–15.4) 1.0000 0.0132 4.4 (1.4–15.4)
SELE 561A3C (Ser128Arg) 0.0467 0.3 (0.1–0.9) 1.0000 0.0467 0.3 (0.1–0.9)
High-risk women
APOE 3932T3C (Cys112Arg) 0.0049 2.4 (1.3–4.6) 0.4367 0.0068 2.4 (1.3–4.6)
SELE 561A3C (Ser128Arg) 0.0493 0.4 (0.1–1.0) 0.8448 0.0297 0.3 (0.1–0.9)
FABP2 2445G3A (Ala54Thr) 0.3026 0.0325 3.0 (1.2–8.9) 0.0305 3.2 (1.2–10.1)
The lowest p value among dominant, recessive, and additive models for each polymorphism is shown in boldface.
CI  confidence interval; OR  odds ratio.
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LDL receptor and LDL receptor-like protein and thus with
an increased serum concentration of cholesterol (22). The
4 allele has previously been associated with CAD (23,24).
Our results indicate that the C allele of the 3932T3C SNP
of APOE was associated with CAD in high-risk women,
consistent with these previous observations (23,24).
The reason for the difference in SNPs associated with
CAD between low-risk men and women or between high-
risk men and women remains to be elucidated. The gender
difference in the association between SNPs and CAD might
be attributable, at least in part, to the difference in the serum
concentration of estrogen between men and women, given
that estrogen exerts various favorable effects on vasomotor
function, including stimulation of the production of nitric
oxide and prostaglandin I2, as well as inhibition of the
release of endothelin-1 by vascular endothelial cells (25). In
addition, given that the 37 polymorphisms examined in the
present study likely represent only a small proportion of
those potentially associated with CAD, it remains possible
that further investigations will uncover polymorphisms that
are associated with this condition in both men and women.
There are several limitations of the present study: 1) given
the complex nature of atherosclerosis, etiologies may vary
among study populations, making replication of the results
difficult. 2) After classifying our study population into high-
and low-risk groups of men and women, the numbers of
individuals in each subgroup were relatively small. 3) Al-
though we selected controls from individuals with no
history of CAD who exhibited normal electrocardiograms at
rest and no signs of myocardial ischemia during exercise
stress testing, without performing coronary angiography, we
could not exclude the possibility that some of these subjects
were affected by CAD. 4) Given that the subjects with
CAD in the present study were survivors of CAD, they are
likely not representative of all CAD patients. However, the
mortality of MI in Japan is approximately one-fifth of that
in the U.S. and one-seventh of that in the U.K. Any
survivor bias present in our study is thus likely to be small.
5) Given the multiple comparisons of genotypes with CAD
in the present study, we adopted a strict criterion of
statistical significance (p 0.005 for association). However,
it is not possible to completely exclude potential statistical
errors such as false-positives. 6) Finally, it is also possible
that one or more of the SNPs associated with CAD in our
study are in linkage disequilibrium with polymorphisms of
other nearby genes that are actually responsible for the
development of this condition.
Despite these various limitations, our present results
suggest that APOE is a susceptibility locus for CAD in
low-risk Japanese men and high-risk women. They also
suggest that MMP3 is a susceptibility locus for CAD in
low-risk women, and that GJA4 constitutes such a locus in
high-risk men. Genotyping of these SNPs may prove
informative for assessment of the genetic risk of CAD in
low- or high-risk men or women.
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Cross Hospital); S. Ichihara, A. Yamada, H. Izawa (Nagoya
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